Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 7/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22711879 | 1.00 | CYP1A2 (0.51) | CYP1A2SCN5AMETDPP4ALDH1A1 | |
| SCHEMBL22711930 | 1.00 | CYP1A2 (0.51) | CYP1A2SCN5AMETDPP4ALDH1A1 | |
| SCHEMBL26308555 | 0.93 | CYP1A2 (0.42) | CYP1A2SCN5AMET | |
| SCHEMBL26308557 | 0.93 | CYP1A2 (0.42) | CYP1A2SCN5AMET | |
| SCHEMBL26308556 | 0.93 | CYP1A2 (0.42) | CYP1A2SCN5AMET | |
| SCHEMBL22711905 | 0.85 | CYP1A2 (0.37) | CYP1A2MET | |
| SCHEMBL22711854 | 0.85 | CYP1A2 (0.37) | CYP1A2MET | |
| SCHEMBL22711884 | 0.85 | CYP1A2 (0.37) | CYP1A2MET | |
| SCHEMBL20203751 | 0.84 | CYP1A2 (0.68) | CYP1A2SCN5AMETALDH1A1 | |
| SCHEMBL20203796 | 0.83 | CYP1A2 (0.68) | CYP1A2SCN5AMETALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230286984-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286984-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286984-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11505554-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20200377507-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286984-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | CYP1A2 2437/4885SCN5A 5/4885MET 4804/4885 |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN5A | CYP1A2 938/4885SCN5A 3/4885MET 4836/4885 |
| US-11505554-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN1B | CYP1A2 923/4885SCN5A 4/4885MET 4836/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | CYP1A2 2127/4885SCN5A 24/4885MET 4014/4885 |
| US-20200377507-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | CYP1A2 2306/4885SCN5A 6/4885MET 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.